NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
Year-over-year SG&A expense growth
Latest
11.58%
↓ 73% vs avg
Percentile
P61
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
42.71%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 11.58% |
| Q3 2025 | -10.06% |
| Q2 2025 | 0.41% |
| Q1 2025 | 11.69% |
| Q4 2024 | 40.71% |
| Q3 2024 | 12.94% |
| Q2 2024 | 5.85% |
| Q1 2024 | 66.01% |
| Q4 2023 | -4.62% |
| Q3 2023 | -7.41% |
| Q2 2023 | 44.19% |
| Q1 2023 | 31.56% |
| Q4 2022 | 0.00% |
| Q3 2022 | 6.74% |
| Q2 2022 | -5.30% |
| Q1 2022 | 177.75% |
| Q4 2021 | 183.11% |
| Q3 2021 | -21.30% |
| Q2 2021 | 1.16% |
| Q1 2021 | 543.30% |
| Q4 2020 | -63.37% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |